A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)

NCT ID: NCT00820196

Last Updated: 2012-09-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 98 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-03-31
• Study Completion Date: 2010-05-31

Brief Summary

Venous leg ulcers are a common, costly and debilitating condition, with few effective treatments. Compression bandaging helps healing, but more than four out of every ten leg ulcers remain unhealed after three months. New treatments to help heal venous ulcers are urgently needed. Initial studies with a new drug product candidate called Nexagon® (developed by CoDa Therapeutics, Inc.) have shown improvements in healing when applied topically to a wound. Further research will be undertaken to assess the safety and activity of Nexagon® when applied to venous leg ulcers in humans, and to obtain further information on the most appropriate dose or doses to apply. A proposed randomised controlled trial aims to further evaluate Nexagon® by randomly allocating (e.g., by the toss of a coin) 90 people with venous leg ulcers to Nexagon® (one of two different doses) or a vehicle (substance containing no medication) to be applied to their ulcer three times over four weeks. Participants will be followed up for 12 weeks to evaluate ulcer healing.

Conditions

Venous Ulcer

Keywords

Venous ulcer; Nexagon; CoDa

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Interventions

Nexagon®

Intervention Type: DRUG

Nexagon® vehicle

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of venous leg ulceration

2. Ankle brachial index of > 0.80 measured during screening or within three months prior to the Day -14 visit.

3. Reference ulcer area greater than 1 cm2 and less than 25 cm2

4. Reference ulcer present for at least 4 weeks

5. Have an ankle circumference of greater than 18 cm

6. Male of female patients aged 18 years or over

7. Able to tolerate effective compression bandaging

8. Patients able to walk independently with or without mobility aids

9. Able and willing to give informed consent

10. Able and willing to attend all follow up visits

Exclusion Criteria

1. Significant change in ulcer size in the screening period screening period

2. Presence of a non-study ulcer within 2.0 cm of the reference ulcer

3. Wound bed with exposed bone, tendon or fascia

4. Patients with leg ulceration etiology other than venous insufficiency

5. Patients who require wheel chairs for normal mobility

6. Patients who have any ulcer (reference or non-reference) which shows signs of clinical infection

7. Patients who have any ulcer (reference or non-reference) positive for β-hemolytic streptococcus upon culture.

8. Patients who are unable to tolerate or comply with the standardized compression bandaging protocol specified in this protocol

9. Female patients who are pregnant or breastfeeding.

10. Patients who are currently taking:

1. Pentoxifylline (Trental®)

2. Immunosuppressive therapy

3. Oral corticosteroid therapy or topical corticosteroid on the leg where the reference ulcer is located

4. Growth factors (e.g. Regranex)

5. Cell cultures or topical skin factors

11. Patients with:

1. Renal insufficiency defined as an estimated GFR which is < 30 mL/min/1.7m2

2. Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range

3. Hepatic insufficiency defined as total bilirubin > 2 mg/dL or serum albumin < 25 g/L

4. HbA1c > 8.5%

5. Hemoglobin < 10 g/dL

6. Hematocrit < 0.30

7. Platelet count < 100,000

12. Patients have had a myocardial infarction within the previous 6 months or patients with unstable angina pectoris

13. Patients with:

1. Collagen vascular disease

2. Severe rheumatoid arthritis

3. Cellulitis or osteomyelitis

14. Patients who have, or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment

15. Patients who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study, e.g., known to abuse alcohol or drugs currently or to have psychological disorders that could affect follow-up care

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

OcuNexus Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Scott Bannan

Role: STUDY_DIRECTOR

OcuNexus Therapeutics, Inc.

Locations

Centre for Clinical Research

San Francisco, California, United States

Pacific Wound Center

Stockton, California, United States

Penn North Centers for Advanced Wound Care

Erie, Pennsylvania, United States

Armstrong County Memorial Hospital

Kittanning, Pennsylvania, United States

Waitemata District Health Board

Auckland, Auckland, New Zealand

District Nursing and Leg Ulcer Service A+Links Home Health

Auckland, , New Zealand

Home Health Services Papakura

Auckland, , New Zealand

Nurse Maude

Christchurch, , New Zealand

Dunedin Hosptial

Dunedin, , New Zealand

Waikato Hospital

Hamilton, , New Zealand

Countries

United States; New Zealand

Other Identifiers

NEX-ULC-001

Identifier Type: -

Identifier Source: org_study_id